Pfizer’s Glucotrol XL Generic Not Cutting Into Andrx’ Market Share
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's introduction of its own Glucotrol XL generic has not impacted Andrx' market share for glipizide extended-release, the generic company said during an Aug. 10 earnings call
You may also be interested in...
Diflucan Generics Launch Following Expiration Of Pfizer Exclusivity
FDA approves numerous ANDAs for tablet, oral suspension and injectable forms of the antifungal upon expiration of Diflucan's six-month pediatric extension. Pfizer is marketing its own generic through its Greenstone subsidiary.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.